Fox S - Search Results

1

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdère P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bézard E. Bastide MF, et al. Among authors: fox s. Prog Neurobiol. 2015 Sep;132:96-168. doi: 10.1016/j.pneurobio.2015.07.002. Epub 2015 Jul 21. Prog Neurobiol. 2015. PMID: 26209473 Review.

2

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.

Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. Henry B, et al. Among authors: fox sh. Mov Disord. 1999 Sep;14(5):744-53. doi: 10.1002/1531-8257(199909)14:5<744::aid-mds1006>3.0.co;2-7. Mov Disord. 1999. PMID: 10495035

3

Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.

Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Nash JE, et al. Among authors: fox sh. Exp Neurol. 2000 Sep;165(1):136-42. doi: 10.1006/exnr.2000.7444. Exp Neurol. 2000. PMID: 10964492

4

Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.

Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Fox SH, et al. Mov Disord. 2001 Jul;16(4):642-50. doi: 10.1002/mds.1148. Mov Disord. 2001. PMID: 11481687

5

Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Henry B, Fox SH, Crossman AR, Brotchie JM. Henry B, et al. Among authors: fox sh. Exp Neurol. 2001 Sep;171(1):139-46. doi: 10.1006/exnr.2001.7727. Exp Neurol. 2001. PMID: 11520128

6

Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.

Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM. Hille CJ, et al. Among authors: fox sh. Exp Neurol. 2001 Nov;172(1):189-98. doi: 10.1006/exnr.2001.7763. Exp Neurol. 2001. PMID: 11681851

7

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.

Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Sieradzan KA, et al. Among authors: fox sh. Neurology. 2001 Dec 11;57(11):2108-11. doi: 10.1212/wnl.57.11.2108. Neurology. 2001. PMID: 11739835 Clinical Trial.

8

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.

Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Fox SH, et al. Mov Disord. 2002 Jan;17(1):145-9. doi: 10.1002/mds.1280. Mov Disord. 2002. PMID: 11835452 Clinical Trial.

9

Potential nondopaminergic drugs for Parkinson's disease.

Silverdale MA, Fox SH, Crossman AR, Brotchie JM. Silverdale MA, et al. Among authors: fox sh. Adv Neurol. 2003;91:273-91. Adv Neurol. 2003. PMID: 12442686 Review. No abstract available.

10

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,580 results

Search Page

Filters